Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CDK20 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDK20 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CDK20 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDK17 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDK17 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CDK17 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDK18 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDK18 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CDK18 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDK10 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDK10 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CDK10 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDK12 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDK12 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CDK12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDK16 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDK16 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CDK16 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDK14 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDK14 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CDK14 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDK11A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDK11A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CDK11A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CCDC51 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CCDC51 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CCDC51 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDC42BPB Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDC42BPB Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CDC42BPB sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CDC42BPA Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CDC42BPA Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CDC42BPA sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CBARP Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CBARP Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of CBARP sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →